Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 25-Mar-24 5:00 PM View:  | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 21-Mar-24 | Option Exercise | 14,491 | $25.30 | $366,622.00 | 169% 8.57K to 23.06K | |
| 25-Mar-24 5:00 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 21-Mar-24 | Planned Option Sale | 14,491 | $35.31 | $511,677.00 | (63%) 23.06K to 8.57K | |
| 22-Mar-24 5:00 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 20-Mar-24 | Option Exercise | 400 | $25.30 | $10,120.00 | 5% 8.57K to 8.97K | |
| 22-Mar-24 5:00 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 20-Mar-24 | Planned Option Sale | 400 | $35.31 | $14,124.00 | (4%) 8.97K to 8.57K | |
| 21-Mar-24 5:01 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 19-Mar-24 | Option Exercise | 12,364 | $25.30 | $312,809.00 | 144% 8.57K to 20.93K | |
| 21-Mar-24 5:01 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 19-Mar-24 | Planned Option Sale | 12,364 | $35.31 | $436,573.00 | (59%) 20.93K to 8.57K | |
| 15-Mar-24 6:39 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 13-Mar-24 | Option Exercise | 62,366 | $17.61 | $1,098,520.00 | 728% 8.57K to 70.94K | |
| 15-Mar-24 6:39 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 13-Mar-24 | Planned Option Sale | 62,366 | $33.74 | $2,104,290.00 | (88%) 70.94K to 8.57K | |
| 14-Mar-24 5:00 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 12-Mar-24 | Option Exercise | 3,884 | $12.98 | $50,414.30 | 45% 8.57K to 12.45K | |
| 14-Mar-24 5:00 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 12-Mar-24 | Planned Option Sale | 3,884 | $32.99 | $128,133.00 | (31%) 12.45K to 8.57K | |
| 29-Feb-24 5:00 PM View: | Khattar Jack A. President, CEO Director | Supernus Pharmaceuticals, I... (SUPN) | 28-Feb-24 | Payment of Exercise | 16,788 | $27.94 | $469,057.00 | (< 1%) 1.95M to 1.94M | |
| 29-Feb-24 5:01 PM View: | Mottola Frank SVP, Quality, GMP, Ops, IT | Supernus Pharmaceuticals, I... (SUPN) | 28-Feb-24 | Payment of Exercise | 460 | $27.94 | $12,852.40 | (6%) 8.24K to 7.78K | |
| 29-Feb-24 5:00 PM View: | Khattar Jack A. President, CEO Director | Supernus Pharmaceuticals, I... (SUPN) | 28-Feb-24 | Option Exercise | 35,000 | -- | -- | 2% 1.92M to 1.95M | |
| 29-Feb-24 5:01 PM View: | Mottola Frank SVP, Quality, GMP, Ops, IT | Supernus Pharmaceuticals, I... (SUPN) | 28-Feb-24 | Option Exercise | 990 | -- | -- | 14% 7.25K to 8.24K | |
| 28-Feb-24 5:01 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 26-Feb-24 | Option Exercise | 5,000 | $9.13 | $45,650.00 | 58% 8.57K to 13.57K | |
| 28-Feb-24 5:01 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 26-Feb-24 | Planned Option Sale | 5,000 | $30.21 | $151,050.00 | (37%) 13.57K to 8.57K | |
| 27-Feb-24 5:02 PM View: | Mottola Frank SVP, Quality, GMP, Ops, IT | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Payment of Exercise | 937 | $29.06 | $27,229.20 | (11%) 8.19K to 7.25K | |
| 27-Feb-24 5:01 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 1,250 | -- | -- | 16% 7.96K to 9.21K | |
| 27-Feb-24 5:00 PM View: | Rubin Jonathan SVP, Chief Medical Officer | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 1,250 | -- | -- | 32% 3.96K to 5.21K | |
| 27-Feb-24 5:02 PM View: | Siebert John M Director | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 3,886 | -- | -- | 5% 84.06K to 87.94K | |
| 27-Feb-24 5:00 PM View: | Martin Tami Tillotson Sr. V.P., Regulatory Affairs | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Payment of Exercise | 485 | $29.06 | $14,094.10 | (< 1%) 87.42K to 86.93K | |
| 27-Feb-24 5:02 PM View: | Mottola Frank SVP, Quality, GMP, Ops, IT | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 1,875 | -- | -- | 30% 6.31K to 8.19K | |
| 27-Feb-24 5:04 PM View: | Gemayel Georges Director | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 3,886 | -- | -- | 29% 13.31K to 17.2K | |
| 27-Feb-24 5:01 PM View: | Dec Timothy C Senior Vice-President & CFO | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 2,500 | -- | -- | 42% 6.0K to 8.5K | |
| 27-Feb-24 5:00 PM View: | Martin Tami Tillotson Sr. V.P., Regulatory Affairs | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 1,250 | -- | -- | 1% 86.17K to 87.42K | |
| 27-Feb-24 5:04 PM View: | Barlow Carrolee Director | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 3,886 | -- | -- | 29% 13.31K to 17.2K | |
| 27-Feb-24 5:01 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Payment of Exercise | 638 | $29.06 | $18,540.30 | (7%) 9.21K to 8.57K | |
| 27-Feb-24 5:00 PM View: | Rubin Jonathan SVP, Chief Medical Officer | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Payment of Exercise | 567 | $29.06 | $16,477.00 | (11%) 5.21K to 4.64K | |
| 27-Feb-24 5:03 PM View: | Hudson Frederick M. Director | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 3,886 | -- | -- | 12% 33.23K to 37.12K | |
| 27-Feb-24 5:01 PM View: | Dec Timothy C Senior Vice-President & CFO | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Payment of Exercise | 1,314 | $29.06 | $38,184.80 | (15%) 8.5K to 7.19K | |
| 27-Feb-24 5:04 PM View: | Newhall Charles W III Director | Supernus Pharmaceuticals, I... (SUPN) | 23-Feb-24 | Grant | 3,886 | -- | -- | 3% 117.09K to 120.97K | |
| 26-Feb-24 5:00 PM View: | Dec Timothy C Senior Vice-President & CFO | Supernus Pharmaceuticals, I... (SUPN) | 22-Feb-24 | Grant | 500 | -- | -- | 9% 5.5K to 6.0K | |
| 26-Feb-24 5:00 PM View: | Martin Tami Tillotson Sr. V.P., Regulatory Affairs | Supernus Pharmaceuticals, I... (SUPN) | 22-Feb-24 | Grant | 750 | -- | -- | < 1% 85.66K to 86.41K | |
| 26-Feb-24 5:02 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 22-Feb-24 | Payment of Exercise | 372 | $27.94 | $10,393.70 | (4%) 8.33K to 7.96K | |
| 26-Feb-24 5:02 PM View: | Rubin Jonathan SVP, Chief Medical Officer | Supernus Pharmaceuticals, I... (SUPN) | 22-Feb-24 | Payment of Exercise | 303 | $27.94 | $8,465.82 | (7%) 4.26K to 3.96K | |
| 26-Feb-24 5:00 PM View: | Mottola Frank SVP, Quality, GMP, Ops, IT | Supernus Pharmaceuticals, I... (SUPN) | 22-Feb-24 | Payment of Exercise | 335 | $27.94 | $9,359.90 | (5%) 6.65K to 6.31K | |
| 26-Feb-24 5:02 PM View: | Bhatt Padmanabh P. Sr. VP of IP, CSO | Supernus Pharmaceuticals, I... (SUPN) | 22-Feb-24 | Grant | 750 | -- | -- | 10% 7.58K to 8.33K | |
| 26-Feb-24 5:02 PM View: | Rubin Jonathan SVP, Chief Medical Officer | Supernus Pharmaceuticals, I... (SUPN) | 22-Feb-24 | Grant | 750 | -- | -- | 21% 3.51K to 4.26K | |
| 26-Feb-24 5:00 PM View: | Martin Tami Tillotson Sr. V.P., Regulatory Affairs | Supernus Pharmaceuticals, I... (SUPN) | 22-Feb-24 | Payment of Exercise | 246 | $27.94 | $6,873.24 | (< 1%) 86.41K to 86.17K | |
| 26-Feb-24 5:00 PM View: | Mottola Frank SVP, Quality, GMP, Ops, IT | Supernus Pharmaceuticals, I... (SUPN) | 22-Feb-24 | Grant | 750 | -- | -- | 13% 5.9K to 6.65K | |
| 22-Feb-24 5:28 PM View: | Khattar Jack A. President, CEO Director | Supernus Pharmaceuticals, I... (SUPN) | 12-Feb-24 | Disposition (other) | 16,500 | -- | -- | (< 1%) 1.94M to 1.92M | |
| 22-Feb-24 5:28 PM View: | Khattar Jack A. President, CEO Director | Supernus Pharmaceuticals, I... (SUPN) | 12-Feb-24 | Acquisition (other) | 16,500 | -- | -- | < 1% 1.92M to 1.94M | |
| 12-Jan-24 5:00 PM View: | Martin Tami Tillotson Sr. V.P., Regulatory Affairs | Supernus Pharmaceuticals, I... (SUPN) | 10-Jan-24 | Option Exercise | 8,000 | $9.24 | $73,920.00 | 9% 85.66K to 93.66K | |
| 12-Jan-24 5:00 PM View: | Martin Tami Tillotson Sr. V.P., Regulatory Affairs | Supernus Pharmaceuticals, I... (SUPN) | 10-Jan-24 | Planned Option Sale | 8,000 | $27.91 | $223,280.00 | (9%) 93.66K to 85.66K | |
| 26-Dec-23 5:00 PM View: | Khattar Jack A. President, CEO Director | Supernus Pharmaceuticals, I... (SUPN) | 22-Dec-23 | Option Exercise | 25,000 | -- | -- | 1% 1.91M to 1.93M | |
| 26-Dec-23 5:01 PM View: | Rubin Jonathan Sr. VP, Chief Medical Officer | Supernus Pharmaceuticals, I... (SUPN) | 22-Dec-23 | Payment of Exercise | 204 | $27.66 | $5,642.64 | (6%) 3.45K to 3.24K | |
| 26-Dec-23 5:01 PM View: | Rubin Jonathan Sr. VP, Chief Medical Officer | Supernus Pharmaceuticals, I... (SUPN) | 22-Dec-23 | Option Exercise | 600 | -- | -- | 21% 2.85K to 3.45K | |
| 26-Dec-23 5:00 PM View: | Khattar Jack A. President, CEO Director | Supernus Pharmaceuticals, I... (SUPN) | 22-Dec-23 | Payment of Exercise | 11,958 | $27.66 | $330,758.00 | (< 1%) 1.93M to 1.92M | |
| 20-Nov-23 5:00 PM View: | Newhall Charles W III Director | Supernus Pharmaceuticals, I... (SUPN) | 16-Nov-23 | Option Exercise | 7,457 | $9.24 | $68,902.70 | 7% 112.13K to 119.59K | |
| 20-Nov-23 5:00 PM View: | Newhall Charles W III Director | Supernus Pharmaceuticals, I... (SUPN) | 16-Nov-23 | Option Sale | 2,500 | $28.01 | $70,025.00 | (2%) 119.59K to 117.09K |
